Skip to main content
. 2017 Mar 1;8(15):24694–24705. doi: 10.18632/oncotarget.15788

Figure 6. Clinical investigation on patients with negative ZAP and positive HBV/HCV.

Figure 6

(A) Representative cores of ZAP immunostaining in TMA. Higher magnification shown inthe box. (Scale bars: 50 μm.) N, nonneoplastic; T, tumor. (B) Statistical analysis of the expression of ZAP of tumor and serum HBsAg and HCVRNA of patients.